BCL-2 inhibitor yields high response in CLL and SLL
- PMID: 24501317
- DOI: 10.1158/2159-8290.CD-NB2013-178
BCL-2 inhibitor yields high response in CLL and SLL
Abstract
Preliminary results from an ongoing phase I clinical trial of the B-cell lymphoma-2 oral inhibitor ABT-199 demonstrated an overall response rate of 84% among 67 patients with relapsed or treatment-resistant chronic lymphocytic lymphoma or small lymphocytic lymphoma.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
